Kristie A. Blum, MD
Professor in Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH, USA
Dr. Blum is Professor in the Division of Hematology. She is board certified in Hematology and Oncology with expertise and extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin (NHL) and Hodgkin lymphoma (HL).
Dr. Blum has been a faculty member at The Ohio State University since 2003; Professor since 2015, Associate Professor from 2010-2015, and Assistant Professor from 2003-2010. She completed her Hematology/Oncology fellowship training at Vanderbilt University from 2000-2001 and Washington University in St. Louis from 2001-2003. Dr. Blum completed Internal Medicine Residency from 1997-2000 at University of Virginia and went to medical school at University of Miami.
Dr. Blum was the Associate Director of the Hematology/Oncology Fellowship Program from 2005-2008 and the Director of the Hematology/Oncology Fellowship from 2008-2013. She continues to lead the Ohio State University Lymphoma Clinical Research Program and currently holds a NCI-sponsored K24 grant to foster her mentoring activities in clinical research for patients with HL and NHL. Dr. Blum also serves on the ABIM Hematology Test Writing Committee, the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin’s Lymphoma Panel. Lastly, she developed and chaired the first two Lymphoma Research Foundation Clinical Research Mentoring Programs from 2013-2015.Dr. Blum has experience in the design, conduct, and publication of phase I-II trials, with focused interest in drug development in lymphomas. She has served as a principal investigator on several CTEP-sponsored phase I/II trials in patients with B-cell CLL and NHL. Through her participation on the Alliance Lymphoma Core Committee, Dr. Blum has had the opportunity to chair 3 CALGB/Alliance/Intergroup studies in patients with NHL and HL. Finally, Dr. Blum has developed several investigator-initiated trials with industry support. She has been involved in several high impact pharmaceutical trials including trials with lenalidomide, ibrutinib, brentuximab, and idelalisib that have led to FDA approvals of several of these agents. Dr. Blum has over 80 published papers including 4 papers recently published in the New England Journal of Medicine regarding the use of ibrutinib and idelalisib in the treatment of CLL, mantle cell, and indolent NHL. She has been invited to speak at two ASH Education Programs, with the first in 2010 on Upcoming diagnostic and therapeutic developments in Hodgkin’s lymphoma and the second in 2015 as chair of the “Contemporary Therapy of Lymphoma” session with a specific talk on “B-cell receptor pathway modulators in NHL.”